EU–India FTA & Healthcare: What It Means

On 27 January 2026, India and the European Union concluded negotiations on a comprehensive Free Trade Agreement, the largest trade pact either side has ever signed. Healthcare is one of the sectors most affected.

With a combined market of 2 billion people, the deal aims to remove tariffs on more than 90% of goods and expand cooperation in services, investment and intellectual property.

For India: a cost, access and capability story

The elimination of tariffs on EU medical equipment and pharmaceuticals is expected to lower input costs for hospitals, accelerate adoption of advanced diagnostics and surgical technologies, and gradually improve patient outcomes. Over time, reduced duties and regulatory alignment could also lower the cost of specialised drugs, particularly as biosimilars and local manufacturing scale up. At the same time, near-zero tariff access to the EU strengthens India's pharmaceutical exports, reinforcing its role as a global supplier of affordable, quality-assured medicines. But these gains come with risks, especially around medical-device regulation, patient safety, and pressure on domestic manufacturers if safeguards aren't strengthened.

For the EU: resilience and market access

The agreement is less about immediate cost reduction and more about resilience and market access. Europe already depends heavily on Indian generics, and the FTA strengthens supply security by reducing reliance on a narrow set of geographies. EU pharmaceutical and med-tech firms gain improved access to India's rapidly growing healthcare market, plus stronger regulatory cooperation and IP enforcement. Most benefits, though, will materialise gradually, since EU tariffs are already low and market-access gains are phased over several years.

The trade-off

On the positive side, the FTA improves access to advanced technology, supports pharma and med-tech collaboration, diversifies global supply chains, and maintains a balanced IP framework that protects both innovation and generics. On the downside, benefits accrue slowly, pricing outcomes aren't guaranteed, compliance costs remain high, and unresolved regulatory and safety issues could dilute impact if not addressed proactively.